感染

订阅

MedSci主页 / 所有栏目 / 感染

真实世界研究显示，基于度鲁特韦和利托那韦增强的达芦那韦（DTG/DRV/r）的双重疗法是HIV-1患者安全且有效的疗法

2019-04-09 不详 网络

关注

众所周知，基于度鲁特韦和利托那韦增强的达芦那韦（DTG/DRV/r）的双重疗法对HIV耐药性具有高基因屏障。本回顾性分析纳入2014年5月至2017年3月在4个波兰中心转为DTG/DRV/r治疗的HIV-1感者，分析治疗48周的结果。共纳入了59名男性和17名女性。中位数基线参数为：年龄42.7岁，CD4细胞计数为560.5细胞/μl，CD4细胞最低为150细胞/μl，先前抗逆转录病毒治疗方案数量

众所周知，基于度鲁特韦和利托那韦增强的达芦那韦（DTG/DRV/r）的双重疗法对HIV耐药性具有高基因屏障。

本回顾性分析纳入2014年5月至2017年3月在4个波兰中心转为DTG/DRV/r治疗的HIV-1感者，分析治疗48周的结果。

共纳入了59名男性和17名女性。中位数基线参数为：年龄42.7岁，CD4细胞计数为560.5细胞/μl，CD4细胞最低为150细胞/μl，先前抗逆转录病毒治疗方案数量为3。转为双重治疗的原因主要是由于病毒学失败（30名患者），先前治疗方案的不良事件（17例患者）和简化治疗（27例患者）。在第48周，70名患者继续治疗，并且中位CD4细胞计数从560.5增加至641.0细胞/μl。 6名患者停止治疗（1例病毒学失败，1例肾小球滤过率（eGFR）下降，1例肌痛，3例失访）。在第48周，六名患者可检测到病毒血症，但仅一名患者的病毒高于200拷贝/ml。在第48周，受试者的血清总胆固醇水平在统计学上显著高于基线刚开始接受双重治疗时的水平（185.8mg/dl vs 174.8mg/dl-p <0.05）。然而，未接受过TDF治疗的患者中，治疗期间脂质参数没有变化。在切换到双重治疗之前，在13.2％的患者中观察到蛋白尿，在第48周时，在7.1％的患者中观察到蛋白尿。

总之，该研究结果表明，基于度鲁特韦和利托那韦增强的达芦那韦（DTG/DRV/r）的双重疗法是安全且有效的。脂质参数水平升高仅出现在双重治疗之前使用基于TDF的方案的患者中。

原始出处：

Elżbieta Jabłonowska, Ewa Siwak, et al., Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients. PLoS One. 2019; 14(1): e0210476.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2045152, encodeId=027b204515226, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Oct 22 21:21:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649232, encodeId=f6bb1649232a0, content=<a href='/topic/show?id=0ef0493990f' target=_blank style='color:#2F92EE;'>#度鲁特韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49399, encryptionId=0ef0493990f, topicName=度鲁特韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c123781077, createdName=zhyy96, createdTime=Wed May 22 06:21:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295223, encodeId=93f212952230c, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Thu Apr 11 04:21:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560148, encodeId=78551560148ce, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32300, encryptionId=ecf3323007c, topicName=利托那韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46815077905, createdName=sunyl12, createdTime=Thu Apr 11 04:21:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566157, encodeId=da6f156615e4b, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32300, encryptionId=ecf3323007c, topicName=利托那韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46815077905, createdName=sunyl12, createdTime=Thu Apr 11 04:21:00 CST 2019, time=2019-04-11, status=1, ipAttribution=)]
    2019-10-22 医者仁心

    #患者安全#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2045152, encodeId=027b204515226, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Oct 22 21:21:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649232, encodeId=f6bb1649232a0, content=<a href='/topic/show?id=0ef0493990f' target=_blank style='color:#2F92EE;'>#度鲁特韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49399, encryptionId=0ef0493990f, topicName=度鲁特韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c123781077, createdName=zhyy96, createdTime=Wed May 22 06:21:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295223, encodeId=93f212952230c, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Thu Apr 11 04:21:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560148, encodeId=78551560148ce, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32300, encryptionId=ecf3323007c, topicName=利托那韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46815077905, createdName=sunyl12, createdTime=Thu Apr 11 04:21:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566157, encodeId=da6f156615e4b, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32300, encryptionId=ecf3323007c, topicName=利托那韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46815077905, createdName=sunyl12, createdTime=Thu Apr 11 04:21:00 CST 2019, time=2019-04-11, status=1, ipAttribution=)]
    2019-05-22 zhyy96

    #度鲁特韦#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2045152, encodeId=027b204515226, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Oct 22 21:21:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649232, encodeId=f6bb1649232a0, content=<a href='/topic/show?id=0ef0493990f' target=_blank style='color:#2F92EE;'>#度鲁特韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49399, encryptionId=0ef0493990f, topicName=度鲁特韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c123781077, createdName=zhyy96, createdTime=Wed May 22 06:21:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295223, encodeId=93f212952230c, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Thu Apr 11 04:21:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560148, encodeId=78551560148ce, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32300, encryptionId=ecf3323007c, topicName=利托那韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46815077905, createdName=sunyl12, createdTime=Thu Apr 11 04:21:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566157, encodeId=da6f156615e4b, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32300, encryptionId=ecf3323007c, topicName=利托那韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46815077905, createdName=sunyl12, createdTime=Thu Apr 11 04:21:00 CST 2019, time=2019-04-11, status=1, ipAttribution=)]
    2019-04-11 chenshujs

    #真实世界#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2045152, encodeId=027b204515226, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Oct 22 21:21:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649232, encodeId=f6bb1649232a0, content=<a href='/topic/show?id=0ef0493990f' target=_blank style='color:#2F92EE;'>#度鲁特韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49399, encryptionId=0ef0493990f, topicName=度鲁特韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c123781077, createdName=zhyy96, createdTime=Wed May 22 06:21:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295223, encodeId=93f212952230c, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Thu Apr 11 04:21:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560148, encodeId=78551560148ce, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32300, encryptionId=ecf3323007c, topicName=利托那韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46815077905, createdName=sunyl12, createdTime=Thu Apr 11 04:21:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566157, encodeId=da6f156615e4b, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32300, encryptionId=ecf3323007c, topicName=利托那韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46815077905, createdName=sunyl12, createdTime=Thu Apr 11 04:21:00 CST 2019, time=2019-04-11, status=1, ipAttribution=)]
    2019-04-11 sunyl12

    #利托那韦#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2045152, encodeId=027b204515226, content=<a href='/topic/show?id=a0555302119' target=_blank style='color:#2F92EE;'>#患者安全#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53021, encryptionId=a0555302119, topicName=患者安全)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Tue Oct 22 21:21:00 CST 2019, time=2019-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649232, encodeId=f6bb1649232a0, content=<a href='/topic/show?id=0ef0493990f' target=_blank style='color:#2F92EE;'>#度鲁特韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49399, encryptionId=0ef0493990f, topicName=度鲁特韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=42c123781077, createdName=zhyy96, createdTime=Wed May 22 06:21:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295223, encodeId=93f212952230c, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Thu Apr 11 04:21:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560148, encodeId=78551560148ce, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32300, encryptionId=ecf3323007c, topicName=利托那韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46815077905, createdName=sunyl12, createdTime=Thu Apr 11 04:21:00 CST 2019, time=2019-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566157, encodeId=da6f156615e4b, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32300, encryptionId=ecf3323007c, topicName=利托那韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e46815077905, createdName=sunyl12, createdTime=Thu Apr 11 04:21:00 CST 2019, time=2019-04-11, status=1, ipAttribution=)]
    2019-04-11 sunyl12

    #利托那韦#

    0